By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > Statin > Rosuvastatin

Rosuvastatin

GMJ
Last updated: 02/06/2026 14:31
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|603 words

Rosuvastatin Drug Profile

What is Rosuvastatin?

Rosuvastatin is a prescription medication belonging to a class of drugs called statins, also known as HMG-CoA reductase inhibitors. It is primarily used to lower cholesterol levels and reduce the risk of cardiovascular disease in adults. Rosuvastatin is considered one of the most potent statins available for treating high cholesterol and preventing heart attacks and strokes.

Uses

Rosuvastatin is approved for several cardiovascular conditions:

  • High cholesterol (hyperlipidemia): Reduces LDL (“bad”) cholesterol and total cholesterol levels while modestly increasing HDL (“good”) cholesterol
  • Primary prevention of cardiovascular disease: Prevents first heart attacks and strokes in people with risk factors like diabetes, high blood pressure, or family history
  • Secondary prevention: Reduces risk of repeat cardiovascular events in patients who have already experienced heart attacks, strokes, or other cardiovascular complications
  • Mixed dyslipidemia: Treats multiple lipid abnormalities including elevated triglycerides and low HDL cholesterol
  • Familial hypercholesterolemia: Manages inherited forms of high cholesterol in both adults and children over 8 years old

How it works

Rosuvastatin works by blocking HMG-CoA reductase, an enzyme that plays a crucial role in cholesterol production in the liver. By inhibiting this enzyme, the medication reduces the liver’s ability to manufacture cholesterol, forcing it to remove more cholesterol from the bloodstream. This mechanism effectively lowers blood cholesterol levels and may also have anti-inflammatory effects that benefit cardiovascular health.

Side effects

Common side effects:

Submit Your Paper
GMJ_Submit_Banner
  • Headache
  • Muscle pain or weakness
  • Nausea
  • Stomach pain or discomfort
  • Constipation
  • Dizziness
  • Fatigue or weakness
  • Memory problems or confusion

Serious side effects requiring immediate medical attention:

  • Severe muscle pain, tenderness, or weakness (possible rhabdomyolysis)
  • Dark-colored urine or decreased urination
  • Yellowing of skin or eyes (jaundice)
  • Severe abdominal pain
  • Unexplained fatigue or fever

Warnings and precautions

  • Liver disease: Patients with active liver disease or persistently elevated liver enzymes should not use rosuvastatin. Regular liver function monitoring may be recommended.
  • Kidney impairment: Dose adjustments are necessary for patients with severe kidney disease, and the medication should be used cautiously in those with kidney problems.
  • Pregnancy and breastfeeding: Rosuvastatin is contraindicated during pregnancy and breastfeeding as it may harm the developing fetus or nursing infant.
  • Muscle disorders: Patients with a history of muscle problems or those taking certain other medications may have increased risk of serious muscle complications.
  • Diabetes risk: Statin therapy may slightly increase blood sugar levels and the risk of developing type 2 diabetes, particularly in predisposed individuals.

Interactions

  • Cyclosporine: Significantly increases rosuvastatin levels, requiring dose reduction or alternative therapy
  • Gemfibrozil: Increases risk of muscle damage when combined with rosuvastatin
  • Warfarin: May enhance blood-thinning effects, requiring closer monitoring of clotting times
  • Antacids containing aluminum or magnesium: Can reduce rosuvastatin absorption when taken simultaneously
  • Certain HIV protease inhibitors: May increase rosuvastatin levels and toxicity risk
  • Fenofibrate: Combination may increase risk of muscle problems
  • Niacin (high doses): May increase risk of muscle complications when used together
  • Red yeast rice supplements: Contains natural statins and may increase risk of side effects

Check interactions with the GMJ Interaction Checker

Dosage

Typical adult dosages range from 5 mg to 40 mg taken once daily, usually in the evening. Most patients start with 10-20 mg daily, with adjustments made based on cholesterol response and tolerability. The maximum recommended dose is 40 mg daily, which is reserved for patients who have not achieved adequate cholesterol reduction with lower doses. Dosage should always be individualized and determined by a healthcare provider based on the patient’s specific condition, risk factors, and response to treatment.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Rosuvastatin." GMJ News — Georgian Medical Journal, 1 June 2026. https://news.gmj.ge/drug/rosuvastatin-6/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Two Words, One Sector: Why STAT News Keeps ‘Health Care’ Separate

STAT News formalizes editorial convention to maintain 'health care' as two words,…

Tracing transgender identity through history: Evidence from ancient civilizations to modern terminology

Historical records from ancient Egypt, Mesopotamia, Greece, and Rome document individuals who…

How Political Pressure on Science Agencies Threatens Public Health Decision-Making

Political interference in federal scientific agencies delays evidence-based decision-making and undermines public…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Simvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Pitavastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Pitavastatin

By
Prof. Giorgi Pkhakadze
01/06/2026

Rosuvastatin

By
Prof. Giorgi Pkhakadze
01/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up